Our team behind the scenes at SXSW | Target Identification, Literature Knowledge Inference

Our team investigates the Target-ID process for GBM using ML methods to identify genes or proteins involved in the development of GBM stem cells, the cells that are resistant to the current treatments.

After creating a knowledge base around the disease (see episode 2) our team created a specific workflow around literature based data. By applying AI models, each interrogating a different component of the data sets, we can generate a list of possible hypotheses for genes involved in GBM.

It is important to train machine learning to do what we consider tedious, yet critical tasks. It frees up scientists to focus their energy on exploring hypotheses.

Watch our team discuss the unique way we approach target identification at BenevolentAI.

More Posts

You Might Also Like

Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020